期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 28, 期 3, 页码 585-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2014.02.002
关键词
Ipilimumab; Tremelimumab; Nivolumab; Immunotherapy; Checkpoint inhibitor; Anti-PD-1; Anti-PD-L1; Anti-CTLA4
资金
- NCI NIH HHS [P30 CA008748] Funding Source: Medline
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it's corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据